Fenofibrate reduces intestinal cholesterol absorption via PPARα-dependent modulation of NPC1L1 expression in mouse

Journal of Lipid Research

Volumn 48, Issue 12, 2007, Pages 2725-2735

  Valasek, Mark A ^a   Clarke, Stephen L ^a   Repa, Joyce J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Dietary cholesterol; Fecal dual isotope method; Fractional cholesterol absorption; Niemann Pick C1 like 1; Peroxisome proliferator activated receptor ; Real time polymerase chain reaction

Indexed keywords

CHOLESTEROL; CHOLIC ACID; EZETIMIBE; FENOFIBRATE; MEMBRANE PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN NPC1L1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG INHIBITION; FECES ANALYSIS; GENE EXPRESSION; INTESTINE ABSORPTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEROL EXCRETION;

ANIMALS; ANTILIPEMIC AGENTS; CHOLESTEROL; CHOLIC ACID; DNA-BINDING PROTEINS; INTESTINAL ABSORPTION; INTESTINE, SMALL; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; PPAR ALPHA; PROCETOFEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER;

EID: 37249042184     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M700345-JLR200     Document Type: Article

References (56)

1. Desvergne, B., and W. Wahli. 1999. Peroxisome proliferatoractivated receptors: nuclear control of metabolism. Endocr. Rev. 20: 649-688.
2. Willson, T. M., P. J. Brown, D. D. Sternbach, and B. R. Henke. 2000. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43: 527-550.
3. Keating, G. M., and D. Ormrod. 2002. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs. 62: 1909-1944.
4. Frick, M. H., O. Elo, K. Haapa, O. P. Heinonen, P. Heinsalmi, P. Helo, J. K. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen, et al. 1987. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317: 1237-1245.
5. Keech, A., R. J. Simes, P. Barter, J. Best, R. Scott, M. R. Taskinen, P. Forder, A. Pillai, T. Davis, P. Glasziou, et al. 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 366: 1849-1861.
6. Rubins, H. B., S. J. Robins, D. Collins, C. L. Fye, J. W. Anderson, M. B. Elam, F. H. Faas, E. Linares, E. J. Schaefer, G. Schectman, et al. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341: 410-418.
7. Lammert, F., and D. Q. Wang. 2005. New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology. 129: 718-734.
8. Altmann, S. W., H. R. Davis, Jr., X. Yao, M. Laverty, D. S. Compton, L. J. Zhu, J. H. Crona, M. A. Caplen, L. M. Hoos, G. Tetzloff, et al. 2002. The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption. Biochim. Biophys. Acta. 1580: 77-93.
9. Altmann, S. W., H. R. Davis, Jr., L. J. Zhu, X. Yao, L. M. Hoos, G. Tetzloff, S. P. Iyer, M. Maguire, A. Golovko, M. Zeng, et al. 2004. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 303: 1201-1204.
10. Field, F. J., E. Born, S. Murthy, and S. N. Mathur. 1998. Caveolin is present in intestinal cells: role in cholesterol trafficking? J. Lipid Res. 39: 1938-1950.
11. Hauser, H., J. H. Dyer, A. Nandy, M. A. Vega, M. Werder, E. Bieliauskaite, F. E. Weber, S. Compassi, A. Gemperli, D. Boffelli, et al. 1998. Identification of a receptor mediating absorption of dietary cholesterol in the intestine. Biochemistry. 37: 17843-17850.
12. Kramer, W., F. Girbig, D. Corsiero, A. Pfenninger, W. Frick, G. Jahne, M. Rhein, W. Wendler, F. Lottspeich, E. O. Hochleitner, et al. 2005. Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane. J. Biol. Chem. 280: 1306-1320.
13. Repa, J. J., S. D. Turley, J. A. Lobaccaro, J. Medina, L. Li, K. Lustig, B. Shan, R. A. Heyman, J. M. Dietschy, and D. J. Mangelsdorf. 2000. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science. 289: 1524-1529.
14. Smart, E. J., R. A. De Rose, and S. A. Farber. 2004. Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc. Natl. Acad. Sci. USA. 101: 3450-3455.
15. Burnett, D. A., M. A. Caplen, H. R. Davis, Jr., R. E. Burrier, and J. W. Clader. 1994. 2-Azetidinones as inhibitors of cholesterol absorption. J. Med. Chem. 37: 1733-1736.
16. Rosenblum, S. B., T. Huynh, A. Afonso, H. R. Davis, Jr., N. Yumibe, J. W. Clader, and D. A. Burnett. 1998. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4- fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem. 41: 973-980.
17. Levy, E., S. Spahis, D. Sinnett, N. Peretti, F. Maupas-Schwalm, E. Delvin, M. Lambert, and M. A. Lavoie. 2007. Intestinal cholesterol transport proteins: an update and beyond. Curr. Opin. Lipidol. 18: 310-318.
18. Valasek, M. A., J. Weng, P. W. Shaul, R. G. Anderson, and J. J. Repa. 2005. Caveolin-1 is not required for murine intestinal cholesterol transport. J. Biol. Chem. 280: 28103-28109.
19. Davis, H. R., Jr., L. J. Zhu, L. M. Hoos, G. Tetzloff, M. Maguire, J. Liu, X. Yao, S. P. Iyer, M. H. Lam, E. G. Lund, et al. 2004. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem. 279: 33586-33592.
20. Garcia-Calvo, M., J. Lisnock, H. G. Bull, B. E. Hawes, D. A. Burnett, M. P. Braun, J. H. Crona, H. R. Davis, Jr., D. C. Dean, P. A. Detmers, et al. 2005. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA. 102: 8132-8137.
21. Yu, L., S. Bharadwaj, J. M. Brown, Y. Ma, W. Du, M. A. Davis, P. Michaely, P. Liu, M. C. Willingham, and L. L. Rudel. 2006. Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J. Biol. Chem. 281: 6616-6624.
22. Knight, B. L., D. D. Patel, S. M. Humphreys, D. Wiggins, and G. F. Gibbons. 2003. Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. J. Lipid Res. 44: 2049-2058.
23. McNamara, D. J., N. O. Davidson, P. Samuel, and E. H. Ahrens, Jr. 1980. Cholesterol absorption in man: effect of administration of clofibrate and/or cholestyramine. J. Lipid Res. 21: 1058-1064.
24. Umeda, Y., Y. Kako, K. Mizutani, Y. Iikura, M. Kawamura, M. Seishima, and H. Hayashi. 2001. Inhibitory action of gemfibrozil on cholesterol absorption in rat intestine. J. Lipid Res. 42: 1214-1219.
25. Vanhanen, H. T., and T. A. Miettinen. 1995. Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. Atherosclerosis. 115: 135-146.
26. Lee, S. S., T. Pineau, J. Drago, E. J. Lee, J. W. Owens, D. L. Kroetz, P. M. Fernandez-Salguero, H. Westphal, and F. J. Gonzalez. 1995. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15: 3012-3022.
27. Peet, D. J., S. D. Turley, W. Ma, B. A. Janowski, J. M. Lobaccaro, R. E. Hammer, and D. J. Mangelsdorf. 1998. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell. 93: 693-704.
28. Turley, S. D., M. W. Herndon, and J. M. Dietschy. 1994. Reevaluation and application of the dual-isotope plasma ratio method for the measurement of intestinal cholesterol absorption in the hamster. J. Lipid Res. 35: 328-339.
29. Schwarz, M., D. W. Russell, J. M. Dietschy, and S. D. Turley. 1998. Marked reduction in bile acid synthesis in cholesterol 7alpha-hydroxylase- deficient mice does not lead to diminished tissue cholesterol turnover or to hypercholesterolemia. J. Lipid Res. 39: 1833-1843.
30. Banerjee, S., A. Smallwood, A. E. Chambers, and K. Nicolaides. 2003. Quantitative recovery of immunoreactive proteins from clinical samples following RNA and DNA isolation. Biotechniques. 35: 450-452, 454, 456.
31. Kurrasch, D. M., J. Huang, T. M. Wilkie, and J. J. Repa. 2004. Quantitative real-time polymerase chain reaction measurement of regulators of G-protein signaling mRNA levels in mouse tissues. Methods Enzymol. 389: 3-15.
32. Shelton, J. M., M. H. Lee, J. A. Richardson, and S. B. Patel. 2000. Microsomal triglyceride transfer protein expression during mouse development. J. Lipid Res. 41: 532-537.
33. van der Veen, J. N., J. K. Kruit, R. Havinga, J. F. Baller, G. Chimini, S. Lestavel, B. Staels, P. H. Groot, A. K. Groen, and F. Kuipers. 2005. Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J. Lipid Res. 46: 526-534.
34. Valasek, M. A., and J. J. Repa. 2005. The power of real-time PCR. Adv. Physiol. Educ. 29: 151-159.
35. Pineda Torra, I., Y. Jamshidi, D. M. Flavell, J. C. Fruchart, and B. Staels. 2002. Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol. Endocrinol. 16: 1013-1028.
36. Tugwood, J. D., I. Issemann, R. G. Anderson, K. R. Bundell, W. L. McPheat, and S. Green. 1992. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11: 433-439.
37. Chianale, J., V. Vollrath, A. M. Wielandt, L. Amigo, A. Rigotti, F. Nervi, S. Gonzalez, L. Andrade, M. Pizarro, and L. Accatino. 1996. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem. J. 314: 781-786.
38. Davis, H. R., Jr., D. S. Compton, L. Hoos, and G. Tetzloff. 2001. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in apoE knockout mice. Arterioscler. Thromb. Vasc. Biol. 21: 2032-2038.
39. Repa, J. J., S. D. Turley, G. Quan, and J. M. Dietschy. 2005. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. J. Lipid Res. 46: 779-789.
40. Grundy, S. M., and G. L. Vega. 1987. Fibric acids: effects on lipids and lipoprotein metabolism. Am. J. Med. 83: 9-20.
41. Wellington, C. L., E. K. Walker, A. Suarez, A. Kwok, N. Bissada, R. Singaraja, Y. Z. Yang, L. H. Zhang, E. James, J. E. Wilson, et al. 2002. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab. Invest. 82: 273-283.
42. Brunham, L. R., J. K. Kruit, J. Iqbal, C. Fievet, J. M. Timmins, T. D. Pape, B. A. Coburn, N. Bissada, B. Staels, A. K. Groen, et al. 2006. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 116: 1052-1062.
43. Temel, R. E., R. G. Lee, K. L. Kelley, M. A. Davis, R. Shah, J. K. Sawyer, M. D. Wilson, and L. L. Rudel. 2005. Intestinal cholesterol absorption is substantially reduced in mice deficient in both ABCA1 and ACAT2. J. Lipid Res. 46: 2423-2431.
44. Guo, Q., P. R. Wang, D. P. Milot, M. C. Ippolito, M. Hernandez, C. A. Burton, S. D. Wright, and Y. Chao. 2001. Regulation of lipid metabolism and gene expression by fenofibrate in hamsters. Biochim. Biophys. Acta. 1533: 220-232.
45. Kok, T., V. W. Bloks, H. Wolters, R. Havinga, P. L. Jansen, B. Staels, and F. Kuipers. 2003. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem. J. 369: 539-547.
46. Turley, S. D., and J. M. Dietschy. 1980. Effects of clofibrate, cholestyramine, zanchol, probucol, and AOMA feeding on hepatic and intestinal cholesterol metabolism and on biliary lipid secretion in the rat. J. Cardiovasc. Pharmacol. 2: 281-297.
47. Davies, J. P., B. Levy, and Y. A. Ioannou. 2000. Evidence for a Niemann-Pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics. 65: 137-145.
48. Plosch, T., J. K. Kruit, V. W. Bloks, N. C. Huijkman, R. Havinga, G. S. Duchateau, Y. Lin, and F. Kuipers. 2006. Reduction of cholesterol absorption by dietary plant sterols and stanols in mice is independent of the Abcg5/8 transporter. J. Nutr. 136: 2135-2140.
49. Chawla, A., J. J. Repa, R. M. Evans, and D. J. Mangelsdorf. 2001. Nuclear receptors and lipid physiology: opening the X-files. Science. 294: 1866-1870.
50. Duval, C., V. Touche, A. Tailleux, J. C. Fruchart, C. Fievet, V. Clavey, B. Staels, and S. Lestavel. 2006. Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem. Biophys. Res. Commun. 340: 1259-1263.
51. Duan, L. P., H. H. Wang, A. Ohashi, and D. Q. Wang. 2006. Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G269-G276.
52. Davies, J. P., C. Scott, K. Oishi, A. Liapis, and Y. A. Ioannou. 2005. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J. Biol. Chem. 280: 12710-12720.
53. Temel, R. E., W. Tang, Y. Ma, L. L. Rudel, M. C. Willingham, Y. A. Ioannou, J. P. Davies, L. M. Nilsson, and L. Yu. 2007. Hepatic Niemann-Pick C1-Like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J. Clin. Invest. 117: 1968-1978.
54. Salen, G., T. Starc, C. M. Sisk, and S. B. Patel. 2006. Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology. 130: 1853-1857.
55. Salen, G., K. von Bergmann, D. Lutjohann, P. Kwiterovich, J. Kane, S. B. Patel, T. Musliner, P. Stein, and B. Musser. 2004. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation. 109: 966-971.
56. Yu, L., K. von Bergmann, D. Lutjohann, H. H. Hobbs, and J. C. Cohen. 2005. Ezetimibe normalizes metabolic defects in mice lacking ABCG5 and ABCG8. J. Lipid Res. 46: 1739-1744.